Search

everythinglearnresearchcommunity

for

Search:↓

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Erlotinib can cause hair loss as a side effect.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Abrocitinib may effectively treat stubborn alopecia universalis.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Eflornithine improved symptoms in Bachmann–Bupp Syndrome patients.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.